Treatment patterns, glycemic control and bodyweight with canagliflozin 300 mg versus GLP1RAs in Type II diabetes patients

Craig I. Coleman, Shivani Pandya, Li Wang, Onur Baser, Jennifer Cai, Mike Ingham, Brahim Bookhart

Research output: Contribution to journalArticle

1 Scopus citations

Abstract

Aim: Real-world effectiveness of canagliflozin 300 mg versus glucagon-like peptide-1 receptor agonists (GLP1RAs) was examined in patients with Type II diabetes. Patients & methods: Patients were selected from the Optum integrated database of administrative claims and electronic health record data (1 January 2013 to 31 March 2015). Results: Patients were less likely to discontinue (p < 0.0001) or switch (p = 0.0048), more likely to add-on treatment (p = 0.0314), and achieve HbA1c <8.0% (p = 0.0364) or weight loss ≥5% (p < 0.0001) with canagliflozin versus GLP1RAs over 9 months. Mean HbA1c was similar at 3-month intervals over 9 months with canagliflozin and GLP1RAs. Conclusion: Patients were less likely to discontinue or switch with canagliflozin than GLP1RA, and were more likely to add-on. Canagliflozin patients were more likely to achieve HbA1c <8.0% and weight loss ≥5% than GLP1RA patients.

Original languageEnglish (US)
Pages (from-to)889-905
Number of pages17
JournalJournal of Comparative Effectiveness Research
Volume8
Issue number11
DOIs
StatePublished - Jan 1 2019
Externally publishedYes

Keywords

  • adherence
  • canagliflozin
  • glucagon-like peptide-1 receptor agonist
  • HbA1c
  • Type II diabetes mellitus
  • weight loss

ASJC Scopus subject areas

  • Health Policy

Fingerprint Dive into the research topics of 'Treatment patterns, glycemic control and bodyweight with canagliflozin 300 mg versus GLP1RAs in Type II diabetes patients'. Together they form a unique fingerprint.

  • Cite this